Related Experiment Videos
Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL)
L Aberg1, H Heiskala, S L Vanhanen
1Children's Hospital, University of Helsinki.
Insights
Lamotrigine (LTG) effectively treated intractable epilepsy in 15 of 16 children with Infantile Neuroaxonal Dystrophy (INCL). This epilepsy treatment improved seizure severity and frequency, with sustained benefits and no severe side effects observed.
Area of Science:
- Neurology
- Pediatric Neurology
- Epileptology
Background:
- Intractable epilepsy is a significant challenge in children with Infantile Neuroaxonal Dystrophy (INCL).
- Limited treatment options exist for managing seizures in INCL patients.
- Lamotrigine (LTG) is an anticonvulsant medication with a known efficacy profile.
Purpose of the Study:
- To evaluate the efficacy and tolerability of lamotrigine (LTG) in pediatric patients diagnosed with Infantile Neuroaxonal Dystrophy (INCL) and intractable epilepsy.
- To assess the impact of LTG on seizure severity, frequency, and overall well-being in this specific patient population.
Main Methods:
- A retrospective analysis was conducted on 16 pediatric patients with INCL and intractable epilepsy treated with lamotrigine (LTG) since 1990.
- Data collected included seizure frequency, seizure severity, patient well-being, and adverse events.
- Treatment efficacy was assessed based on the reduction in seizure activity and sustained therapeutic effects.
Main Results:
- Lamotrigine (LTG) demonstrated a favorable response in 15 out of 16 INCL patients.
- Significant reductions in seizure severity were observed in 15/16 patients, and seizure frequency decreased in 14/16 patients.
- Sustained therapeutic effects and a beneficial impact on overall well-being were noted in the majority of patients (14/16), with no severe adverse events reported.
Conclusions:
- Lamotrigine (LTG) is a highly effective and well-tolerated treatment option for intractable epilepsy in children with Infantile Neuroaxonal Dystrophy (INCL).
- LTG significantly improves seizure control and enhances the quality of life for INCL patients.
- While LTG showed sustained efficacy in combination therapy, it did not maintain efficacy in monotherapy, suggesting the need for combination treatment strategies.
Abstract:
Since 1990, altogether 16 INCL patients received lamotrigine (LTG) because of intractable epilepsy. The response to LTG was favorable in 15/16 children. The severity of seizures decreased significantly in 15/16 patients, the frequency of seizures decreased in 14/16, and the effects were maintained. In addition, LTG had a beneficial effect on the well-being of 14/16 children. LTG failed to maintain it's efficacy in monotherapy. No severe side effects were found.